These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 20432882)

  • 1. Patent dispute: Delhi High Court gives a boost to access to affordable medicines.
    Menghaney L
    Indian J Med Ethics; 2010; 7(2):97-100. PubMed ID: 20432882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Access to medicine and the dangers of patent linkage: lessons from Bayer Corp v. Union of India.
    Tsui M
    J Law Med; 2011 Mar; 18(3):577-88. PubMed ID: 21528741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is India ready to lead the battle for fair access to medicines?
    Lancet Oncology
    Lancet Oncol; 2013 May; 14(6):437. PubMed ID: 23639313
    [No Abstract]   [Full Text] [Related]  

  • 4. Novartis challenges India's drug patent laws in Supreme Court.
    Billingsley M
    BMJ; 2012 Feb; 344():e1279. PubMed ID: 22354594
    [No Abstract]   [Full Text] [Related]  

  • 5. India's patent laws under pressure.
    Roderick P; Pollock AM
    Lancet; 2012 Sep; 380(9846):e2-4. PubMed ID: 22988579
    [No Abstract]   [Full Text] [Related]  

  • 6. Taking TRIPS to India--Novartis, patent law, and access to medicines.
    Mueller JM
    N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473
    [No Abstract]   [Full Text] [Related]  

  • 7. How do public health safeguards in Indian patent law affect pharmaceutical patenting in practice?
    Sampat BN; Amin T
    J Health Polit Policy Law; 2013 Aug; 38(4):735-55. PubMed ID: 23645877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amendments to the Canadian Patent Act to address drug access: is help on the way?
    Penner MD; Narayanan P
    Food Drug Law J; 2005; 60(3):459-70. PubMed ID: 16304751
    [No Abstract]   [Full Text] [Related]  

  • 9. On access and accountability--two Supreme Court rulings on generic drugs.
    Boumil MM; Curfman GD
    N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
    [No Abstract]   [Full Text] [Related]  

  • 10. Intellectual property. Challenges to India's pharmaceutical patent laws.
    Sampat BN; Shadlen KC; Amin TM
    Science; 2012 Jul; 337(6093):414-5. PubMed ID: 22767892
    [No Abstract]   [Full Text] [Related]  

  • 11. Will the Modi government succumb to US and industry pressure to modify its pro-access pharmaceutical patent policy?
    Baker BK
    Expert Opin Ther Pat; 2015 Jun; 25(6):625-8. PubMed ID: 25704359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. India: New patent law may restrict access to HIV/AIDS treatments.
    Cruess G
    HIV AIDS Policy Law Rev; 2005 Aug; 10(2):28-30. PubMed ID: 16365971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
    Halliburton M
    Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teva Pharmaceuticals v. Sandoz: availability of generic glatiramer acetate and the impact to patent litigation claim construction.
    Fogel LE; Ray CJ
    Expert Opin Ther Pat; 2015 Jan; 25(1):1-4. PubMed ID: 25363310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. India's patent case victory rattles Big Pharma.
    Chatterjee P
    Lancet; 2013 Apr; 381(9874):1263. PubMed ID: 23589911
    [No Abstract]   [Full Text] [Related]  

  • 16. Canadian court upholds Glaxo's patent on AZT.
    Elliott R
    Can HIV AIDS Policy Law Rev; 2001; 6(1-2):53-7. PubMed ID: 11837029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legal challenge to India's patent laws threatens access to generic drugs, says charity.
    Moszynski P
    BMJ; 2011 Sep; 343():d5753. PubMed ID: 21908529
    [No Abstract]   [Full Text] [Related]  

  • 18. Comment: compulsory licensing of patented pharmaceutical inventions: evaluating the options.
    Reichman JH
    J Law Med Ethics; 2009; 37(2):247-63. PubMed ID: 19493070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "To patent or not to patent? the case of Novartis' cancer drug Glivec in India".
    Gabble R; Kohler JC
    Global Health; 2014 Jan; 10():3. PubMed ID: 24393270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered in India--patent law 2.0.
    Kapczynski A
    N Engl J Med; 2013 Aug; 369(6):497-9. PubMed ID: 23862973
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.